Removal of "93 capsules + 14 in back-up, total", change to "100 capsules" Change from "(93 capsules)" to "(100 capsules)" Point 9.8.1, remove "in the patient diary" Reason: Correction to the right number of capsules. Patients do not have any diaries for side effects. f) Page 35. Adjustment and correction of errors in Table 10 .1. STUDY ASSESSMENT SCHEDULE. Addition of time intervals for the various follow-ups. g) Page 36, 10.2, last sentence of paragraph 1 "The patient and relatives will receive a diary in which they are encouraged to record the date and nature of any adverse events." is removed. Reason: Patients do not have any diaries for side effects. h) Page 36. Under the heading Alert of Adverse Reactions, the following sections are removed: "… will be sent or faxed to the coordinating center…" and "… If no discharge form is received by 6 weeks the center will be prompted by fax or email to send the discharge form. If the patient is still in hospital the local research team will be asked…"
Regarding the system for event reporting, the sentence: "At these follow ups the GP or other responsible physician will be asked by the local EFFECTS team about adverse events." is removed. Reason: We want to simplify the process for the local centre. In order to maintain security, we will encourage patients and relatives to call the local centre to report. Our experience during the pilot phase is that this system works betterboth patients and relatives find it easier to contact their local physician or nurse. The reference saying that we will have a special system with pre-stamped envelopes and a web-based solution for patients and relatives is thus omitted. Under point 10.3, we have re-worded the text so that it corresponds with the follow-up carried out (typographical error in the protocol on this page). We are therefore adjusting the text to: face-to-face follow-up locally at 6 months and additional central follow-up (survey) at 6 and 12 months. We will not have any web-based follow-up available for patients and relatives. i) Page 37. Sample size calculation: Minor modification, since the sister study AFFINITY is expected to include 1,600 patients (not 1,500), the total included in the study is adjusted to 6,100 (not 6,000).
The following text is removed: "The trial steering committee (TSC) will review the target sample size at the end of the feasibility phase and adjust this based on:
• Advice from the DMC • Accruing data on o the enrolment into specific pre-specified subgroups o completeness of follow up o distribution of mRS categories in the population of enrolled subjects (i.e. both treatment groups combined), overall and in specific patient categories (e.g. those with motor deficits, aphasia, etc.)
For example, if the distribution of mRS is different to that anticipated, then the sample size might need to be increased. This approach has the advantage that such sample size adjustments can be made without reference to the accumulating blinded data, and avoids the need for conditional power calculations which can be unreliable."
Reason: This text is not correct.
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Malmö, Sweden: 20170920 j) Page 39. Motor function -NIHSS, speech -NGTA The following sentence is removed: "In this case the total population will be 1550; if however trial eligibility has had to be changed we will report the 1500 from the main phase as main findings, and the 50 from the feasibility phase separately." Reason: We do not use the Fugl-Meyer Scale or ANELT (typographical error in the protocol on this page). k) Page 40. Adjustment of the number of EQ5D-5L measurements during the main phase: a reduction from having measured EQ5D-5L during the pilot phase on inclusion on 6 occasions (1 week, 4 weeks, 3 months, 6 months and 12 months) to measuring at 4 measurement points (inclusion, and 3, 6 and 12 months). Reason for this adjustment: We do not need 6 measurement points for quality of life, and we want to reduce the burden for patients. l) Page 43, Section 15.3.1, paragraph 3. We are adjusting the wording to make it clearer that SUSAR must be reported via the helpline within 24 hours instead of by fax.
The sentence now reads "SUSAR should be reported to the helpline (073-663 74 44) within 24 h". The sentence "and must sign the EFFECTS trial prescription form for the trial medication." is deleted. Does not apply. n) Print-out form: Remove "If there have been changes to the medication at baseline". Medications must instead be listed when printing out the form. Reason: The previous reasoning was a little unclear. We are making this change to make it clearer and simpler. o) Changes to "Patient and relative information 18 May 2015 version 3"clarification of possible side effects of fluoxetine, and request to be able to use register data. Changes to the text are marked in red in the accompanying document. This red marking will then be removed. The text reads:
"I also give my consent for information about being signed off sick, care-related consumption of resources and survival to be obtained from public registers. All data will be processed in anonymised form.
Your personal data will be dealt with in accordance with the Swedish Data Protection Act. Danderyd Hospital is responsible for your personal data. You are entitled to receive an extract of your personal data once a year, and can contact Eva Isaksson (tel. no. +46 (0)8 123 576 93) to obtain this." Self-reported quality of life will during the pilot phase, measured at baseline, 1 week, patient or proxy), 4 weeks, 3 moths [sic], 6 months, and at 12 months of follow up will be measured using the EuroQoL 5 Dimensions (EQ5D-5L) scale.
In the main phase, EQ5D will be measured at inclusion, at 6 and 12 months follow-up.
After having received a number of questions from participating centres and our monitors, we would like to clarify the sentence about the main phase. First, a little background. We have close cooperation with our sister study FOCUS in Edinburgh. FOCUS measures EQ5D at 6 and 12 months centrally via a survey that is sent to the patient's home. In this follow-up, only the question section of EQ5D is used, not the VAS thermometer (page 2 in EQ5D). The reason for this is that an additional surveythe Stroke Impact Scale (SIS) -includes a VAS thermometer. We have been concerned that the patients would conflate the different thermometers. At the same time, we have been keen to be able to pool data with FOCUS (Edinburgh). This means that in the two central forms, our data and Edinburgh's data are identical, the questions in EQ5D.
At the same time, our ambition has been to make the health economic analysis in Sweden clearer.
We have therefore introduced EQ5D on inclusion and at the local repeat visit, at 6 months. Because we wanted it to be possible to compare inclusion with the 6-month check, we used the entire EQ5D instrument, i.e. the 5 questions including the VAS thermometer at: a) Local measurement of the entire EQ5D on inclusion (not included in Edinburgh) b) Local measurement of the entire EQ5D at 6 months (not included in Edinburgh)
In order for this to be completely clear, we have made certain changes in 10.1 on page 35 of the Research Protocol. The text marked in red and the figures are stated to highlight what is commented on under the table. We will change the time intervals to months (after 1 weeksee the heading row marked in red). Instead of writing 4 weeks, we are now writing 1 month, etc. The figures in the table and the text colour will be removed in the published protocol.
1. The company that manufactures fluoxetine has updated its SPC. They now state that if metoprolol is used in the case of heart failure, fluoxetine is contraindicated. EFFECTS' Steering Committee and Safety Committee have made the assessment that this applies to serious heart failure, that it may be clinically significant in the case of more advanced heart failure (NYHA Grad IIB -IV) and especially in higher doses, and that in the case of simultaneous treatment with metoprolol and fluoxetine one should be attentive to the interaction and should follow up on the patient soon after inclusion with clinical monitoring including ECG. In the annual safety report to the Swedish Medical Products Agency, we have carried out a thorough analysis in relation to this problem, and it does not recur here. In summary, EFFECTS' steering group is of the opinion that this did not give cause for any change to the study, as this falls under the exclusion criterion pharmaceuticals that have significant interactions with SSRIs. All centres have been notified of this serious interaction, and we have clarified this exclusion criterion through the following addition to our research plan.
"Fluoxetine is contra-indicated in combination with metoprolol used in cardiac failure New York Heart Association Grade IIIB and IV. At higher doses of metoprolol used in heart failure indication one should be vigilant of the interaction and early after enrollment monitor the patient with clinical monitoring including ECG."
Page 25 in the Research Plan 2. We have previously written that participation in another CTIMP does not automatically rule out participation in EFFECTS, but that it is important not to overburden patients with studies.
In the section about co-enrolment, we now mention the TIMING study and write:
"It is allowed to co-enroll patients in EFFECTS and the TIMING study. The intervention in TIMING is early vs delayed start of NOAC in patients with acute stroke and atrial fibrillation. Thus, all patients would receive NOAC either <=4 days or > 5 days from the acute stroke."
Page 26 in the Research Plan 3. We have noted that our protocol has not specified how long we recommend stopping in the event of suspected side effects and whether we will permit restarting medication after a longer stop. We have now clarified this in the updated version. We write:
1. Our primary outcome measure is an ordinal scale called the modified Rankin Scale (mRS). The scale, which goes from 0 (no symptoms) to 6 (dead), is the most common outcome measure for stroke. The mRS is most commonly carried out at a repeat visit, but it can also be done by telephone or via a survey. Carrying out surveys during repeat visits can be time-consuming, particularly in the case of large studies, and our colleagues in Edinburgh have therefore developed a scale called the simple modified Rankin Scale questionnaire (smRSq). This consists of five questions, and can be carried out as a survey or by telephone. smRSq is validated in English, but not in Swedish. In our research plan, we stated that we planned to carry this out during 2013see below. However, because we have been forced to focus on other issues (preparing randomisation systems, eCRF, inclusion of patients in the study), we have not been able to carry out the planned study. Since several years have passed since we applied, we believe that it is important to clarify our position on this matter to the Ethical Review Board.
We wrote the following in version 4.8 of the research plan, on page 22. The wording remains unchanged since the first application, which was approved on 30 September 2013:
"Modified Rankin Scale (mRS) (based ordinal analysis to maximize power and to avoid problems including patients with an mRS > 2 prior to their stroke) at 6 months after randomization. Patient who die would be attributed a score of 6 for this analysis.
The mRS is an extremely simple, time efficient measure with well-studied reliability used to categorize level of functional outcome. It has been used extensively in large, multicentre stroke trials.
Any misclassification of patients into an inappropriate mRS category may reduce the power of the trial. To minimize misclassification and intermodality differences we will use the simple modified Rankin Scale questionnaire (smRSq) described by Bruno and colleagues. This has been delivered by both telephone and postal questionnaires and has been completed by patients and proxies (Bruno 2010 (Bruno , 2011 ) (Dennis 2012) (Lundström in early manuscript 2013)."
What we now intend to do is to investigate whether the survey that we sent out at 6 and 12 months gives similar results compared with a traditional assessment during a repeat visit.
This does not involve any additional burden for the patient compared with how we do things now. Every participant in the study already answers the five questions that form the basis for smRSq. What is being added is a number of physicians and nurses carrying out a traditional assessment of mRS at the 6 month repeat visit.
All the information required in order to carry out a regular mRS is obtained during the ordinary repeat visit. I have personally tried out doing this at a number of repeat visits, and it does not make the repeat visit any longer or more difficult for the patient.
However, since the planned comparison between smRS and mRS has not yet been carried out, we would like to apply with this amendment to carry out the sub-study.
This will affect a total of 65 individuals.
The method for carrying out a study within a study is called Study Within A Trial (SWAT) in English (Anon 2012) . We intend to register this study in a register called the Northern Ireland Hub for Trials Methodology.
The changes in version 4.9 of the research plan are marked in red below:
"Modified Rankin Scale (mRS) (van Swieten 1988) (based ordinal analysis to maximize power and to avoid problems including patients with an mRS > 2 prior to their stroke) at 6 months after randomization. Patient who die would be attributed a score of 6 for this analysis.
The mRS is an [sic] simple, time efficient measure with well-studied reliability used to categorize level of functional outcome. It has been used extensively in large, multicentre stroke trials.
Any misclassification of patients into an inappropriate mRS category may reduce the power of the trial. To minimize misclassification and intermodality differences we will use the simple modified Rankin Scale questionnaire (smRSq) described by Bruno and colleagues. This has been delivered by both telephone and postal questionnaires and has been completed by patients and proxies (Bruno 2010 (Bruno , 2011 Dennis 2012) . The smRSq has been validated in English (Bruno 2010 (Bruno , 2011 Dennis 2012) The smRSq is sends [sic] to patients by the Trial Manager Assistant (TMA) at 6 and 12 month post randomisation. If the patient does not answer, the TMA contacts the patient by phone and reminds them to send in the questionnaire. If they have difficulty answering for themselves TMA helps them fill in the form by phone.
Statistics

Number of patients
The primary aim of the study is to evaluate whether the mRs-score measured by the smRSq differs from a mRS-score measured by a clinician. It has been defined that one step or more disparity in the mRs-score is a significant difference. A study of similar character has never been performed before and due to the nature of the study, an initial study, the sample size is not formulated in the guise of power, risk level, or clinical difference. The number of patients participating in the study is therefore primarily chosen for clinical reasons, not statistical, and 60 patients will be included in the study. In order to compensate for included patients not valid for efficacy analysis it is planned to enrol up to 65 patients in the study in order to have 60 patients valid for efficacy analysis. The attrition rate is estimated to be about 6%.
Statistical methods and data management
Statistical comparisons in order to test differences between dependent observations will be made by use of pair-wise Student's t-test for correlated means and statistical comparisons between two independent groups will be made by use of the Student's t-test for uncorrelated means., [sic] after validation for normal distribution by use of the Shapiro Wilk test. The Pearson correlation coefficient will be used in order to test independence between variables. In addition to that descriptive statistics will be used to characterize the data. All analyses will be carried out by use of the SAS system (The SAS system for Windows 9.4., SAS Institute Inc, Cary, NC, USA.) and the 5% levels of significance will be considered. In the case of a statistically significant result the probability value (p-value) will be given. The results will be presented in a cross table. The proportion of full agreement will be given in percent and 95% Confidence Interval, as well as weighted and not weighted Kappa value.
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